Proceedings of the NHLBI Workshop on Artificial Intelligence in Cardiovascular Imaging: Translation to Patient Care.

Artificial intelligence (AI) promises to revolutionize many fields, but its clinical implementation in cardiovascular imaging is still rare despite increasing research. We sought to facilitate discussion across several fields and across the lifecycle of research, development, validation, and implementation to identify challenges and opportunities to further translation of AI in cardiovascular imaging. Furthermore, it seemed apparent that a multidisciplinary effort across institutions would be essential to overcome these challenges. This paper summarizes the proceedings of the National Heart, Lung, and Blood Institute-led workshop, creating consensus around needs and opportunities for institutions at several levels to support and advance research in this field and support future translation.

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures The content of this manuscript is solely the responsibility of the authors and does not necessarily reflect the official views of the National Heart, Lung, and Blood Institute, National Institutes of Health, or the United States Department of Health and Human Services. The National Heart, Lung, and Blood Institute (NHLBI) Workshop on Artificial Intelligence in Cardiovascular Imaging: Translating Science to Patient Care, held on June 27 and 28, 2022, was supported by the Division of Cardiovascular Sciences, NHLBI. Dr Antani has been supported by the Intramural Research Program of the National Library of Medicine and National Institutes of Health (NIH). Dr Arnaout has been supported by the NIH, the Department of Defense, and the Gordon and Betty Moore Foundation. Dr Dey has received software royalties from Cedars Sinai; and funding support from NIH/NHLBI grants (1R01HL148787-01A1 and 1R01HL151266). Dr Leiner has served on the Advisory Board for Cart-Tech B.V. and AI4Med; has been a clinical advisor for Quantib B.V.; has been a consultant for Guerbet; and has received funding support from the Netherlands Heart Foundation. Dr Sengupta has served on the Advisory Boards of Echo IQ and RCE Technologies; and has received funding support from NSF Award: 2125872 and NRT-HDR: Bridges in Digital Health. Dr Shah has received consulting fees from AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squib, Cytokinetics, Edwards Lifesciences, Eidos, Gordian, Intellia, Ionis, Merck, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sardocor, Shifamed, Tenax, Tenaya, and United Therapeutics; and has received funding support from the NIH (U54 HL160273, R01 HL140731, R01 HL149423), Corvia, and Pfizer. Dr Slomka has received software royalties from Cedars Sinai; and has received funding support from the NIH/NHLBI grant 1R35HL161195-01. Dr Williams has been a speaker at lectures sponsored by Canon Medical Systems and the Siemens Healthineers; and has received funding support from the British Heart Foundation (FS/ICRF/20/26002). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.